While stocks fell deep into the red across the board Wednesday, Glaukos Corp.'s (Laguana Hills, Calif.) share price (NYSE; GKOS) moved into the g reen by just a pinch after the company reported positive long-term data from an international study of its micro-bypass stent for glaucoma.